The first Phase II trial will study the effects of multiple doses of CMX001 given to stem cell and kidney transplant recipients with BK viruria. Further studies are planned to explore the ability of CMX001 to prevent cytomegalovirus disease.
CMX001 is being developed for the treatment of smallpox infection and other double stranded DNA virus infections that cause significant human morbidity and mortality.
George Painter, president and CEO of Chimerix, said: “The safety and high oral availability demonstrated by CMX001 in the Phase I trial has exceeded our original expectations. We believe that CMX001 has potential for prevention and treatment of many serious and potentially fatal infections such as smallpox, cytomegalovirus, BK virus and adenovirus.”